. "Appendix 16: Mycobacterium tuberculosis." Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press, 2000.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Vaccines for the 21st Century: A Tool for Decisionmaking
Table A16–1 Incidence and Mortality Rates of TB Infections
Age Groups
Population
Incidence Rates (per 100,000)
% Distribution of Cases
Cases
<1
3,963,000
2.66
0.0046
106
1–4
16,219,000
2.66
0.0189
432
5–14
38,056,000
2.66
0.0445
1,014
15–24
36,263,000
4.69
0.0746
1,700
25–34
41,670,000
9.82
0.1794
4,090
35–44
42,149,000
9.82
0.1815
4,137
45–54
30,224,000
11.63
0.1542
3,515
55–64
21,241,000
11.63
0.1084
2,470
65–74
18,964,000
15.85
0.1318
3,005
75–84
11,088,000
15.85
0.0771
1,757
85+
3,598,000
15.85
0.0250
570
Total
263,435,000
8.65
1.0000
22,795
Age Groups
Population
Mortality Rates (per 100,000)
% Distribution of Cases
Cases
<1
3,963,000
0.00
0.0000
0
1–4
16,219,000
0.02
0.0020
3
5–14
38,056,000
0.00
0.0007
1
15–24
36,263,000
0.04
0.0102
15
25–34
41,670,000
0.18
0.0495
73
35–44
42,149,000
0.33
0.0928
137
45–54
30,224,000
0.50
0.1030
152
55–64
21,241,000
0.96
0.1382
204
65–74
18,964,000
1.65
0.2121
313
75–84
11,088,000
3.22
0.2419
357
85+
3,598,000
6.14
0.1497
221
Total
263,435,000
0.56
1.0000
1,476
VACCINE DEVELOPMENT
The committee assumed that it will take 15 years until licensure of a TB vaccine and that $360 million needs to be invested. Table 4–1 summarizes vaccine development assumptions for all vaccines considered in this report.
VACCINE PROGRAM CONSIDERATIONS
Target Population
For the purposes of the calculations in this report, it is assumed that the target population for this vaccine is 500,000 high-risk people. 300,000 of those people are high-risk individuals in multi-drug-resistant areas. It was assumed that 90% of the selective high-risk population would utilize the vaccine and that
